PD-1 related transcriptome profile and clinical outcome in diffuse gliomas

Background: PD-1 plays a critical part in control of immune response to malignancy. Anti-PD-1 treatment is a hopeful strategy to improve the dismal prognosis of gliomas. To characterize the role of PD-1 in diffuse gliomas, we investigated its related biological process at transcriptome level and its...

Full description

Bibliographic Details
Main Authors:	Shuai Liu, Zheng Wang, Yinyan Wang, Xing Fan, Chuanbao Zhang, Wenbin Ma, Xiaoguang Qiu, Tao Jiang
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2018-02-01
Series:	OncoImmunology
Subjects:	checkpoint inhibitors: glioma immunotherapy pd-1 rna-seq
Online Access:	http://dx.doi.org/10.1080/2162402X.2017.1382792

Similar Items

Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives
by: Pasquale Persico, et al.
Published: (2021-03-01)

PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor
by: Zhi-liang Wang, et al.
Published: (2019-02-01)

From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review
by: Moksada Regmi, et al.
Published: (2024-02-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
by: Tianrui Yang, et al.
Published: (2021-02-01)

The co-inhibitory immune checkpoint proteins B7-H1(PD-L1) and B7-H4 in high grade glioma: From bench to bedside
by: Ying Qi, et al.
Published: (2024-01-01)

Immune Microenvironment and Immunotherapies for Diffuse Intrinsic Pontine Glioma
by: Yujia Chen, et al.
Published: (2023-01-01)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
by: Alice L. Hung, et al.
Published: (2018-08-01)

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
by: Jiawen Qian, et al.
Published: (2018-10-01)

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
by: Seri Jeong, et al.
Published: (2021-10-01)

A Novel Oral Arginase 1/2 Inhibitor Enhances the Antitumor Effect of PD-1 Inhibition in Murine Experimental Gliomas by Altering the Immunosuppressive Environment
by: Paulina Pilanc, et al.
Published: (2021-08-01)

Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma
by: Nusrat Jahan, et al.
Published: (2019-05-01)

Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
by: Grace Wakabayashi, et al.
Published: (2019-12-01)

PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action
by: Ewa Surmiak, et al.
Published: (2021-10-01)

IMMUNE RESISTANCE VIA A PD-1/PD-L1 MECHANISM IN GLIOBLASTOMA
by: V.S. KUSHNIROVA, et al.
Published: (2023-12-01)

Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era
by: SHAN Baoen
Published: (2023-09-01)

Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges
by: Fang Yang, et al.
Published: (2021-12-01)

Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
by: Ofek Mussafi, et al.
Published: (2022-08-01)

Meta-analysis of the correlation between glioma prognosis and PD-1/PD-L1 expression
by: Chang-cheng Ren, et al.
Published: (2023-12-01)

Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials
by: C. Bryce Johnson, et al.
Published: (2018-04-01)

Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy
by: Tao Wang, et al.
Published: (2022-05-01)

Effectiveness of chemotherapy after anti‐PD‐1 blockade failure for relapsed and refractory Hodgkin lymphoma
by: Beatrice Casadei, et al.
Published: (2020-11-01)

Construction of a telomere-related gene signature to predict prognosis and immune landscape for glioma
by: Qin Xie, et al.
Published: (2023-06-01)

Mouse Preclinical Cancer Immunotherapy Modeling Involving Anti-PD-1 Therapies Reveals the Need to Use Mouse Reagents to Mirror Clinical Paradigms
by: Arta M. Monjazeb, et al.
Published: (2021-02-01)

Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy
by: Areti Strati, et al.
Published: (2023-06-01)

Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for  Non-small Cell Lung Cancer
by: Sixuan WU, et al.
Published: (2019-07-01)

Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy
by: Annoor Awadasseid, et al.
Published: (2023-01-01)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
by: Qian Li, et al.
Published: (2022-12-01)

Pretreatment Peripheral B Cells Are Associated With Tumor Response to Anti-PD-1-Based Immunotherapy
by: Shumin Yuan, et al.
Published: (2020-10-01)

CARD-Associated Risk Score Features the Immune Landscape and Predicts the Responsiveness to Anti-PD-1 Therapy in IDH Wild-Type Gliomas
by: Depei Li, et al.
Published: (2021-03-01)

Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points
by: Janina Świderska, et al.
Published: (2021-12-01)

Radiotherapy combined with anti-CEACAM1 immunotherapy to induce survival advantage in glioma
by: Jinhu Li, et al.
Published: (2023-03-01)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019-05-01)

Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
by: Ranjan Pathak, et al.
Published: (2020-12-01)

Immunotherapy approaches for the treatment of diffuse midline gliomas
by: Joshua D. Bernstock, et al.
Published: (2022-12-01)

Expression of PD-L1 in Malignant Soft Tissue Neoplasm and Their Correlation with Clinicopathological Parameters
by: Ashutosh Mishra, et al.

Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study
by: Alessandro Rizzo, et al.
Published: (2022-08-01)

Immune and Clinical Features of CD96 Expression in Glioma by in silico Analysis
by: Qiang Zhang, et al.
Published: (2020-06-01)

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
by: Arefeh Zabeti Touchaei, et al.
Published: (2024-03-01)

Biomarkers in immune checkpoint inhibition therapy for cancer patients: what is the role of lymphocyte subsets and PD1/PD-L1?
by: Puneet Singh, et al.
Published: (2019-02-01)

Immune Checkpoint Inhibitors in Human Glioma Microenvironment
by: Amina Ghouzlani, et al.
Published: (2021-07-01)